How to stop taking adagrasib (Krazati) and possible symptoms and countermeasures after stopping the drug

Adagrasiib (Krazati) is an oral targeted drug mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. During treatment, patients may sometimes need to discontinue medication due to adverse reactions, evaluation of efficacy, or other health conditions. The method of discontinuing medication should be guided by your doctor. It is not recommended to stop medication suddenly on your own. Usually, doctors will gradually reduce the dose or short-term interruption based on the patient's physical condition, treatment cycle and medication dosage to minimize the physical burden and risk of disease recurrence.

After stopping the drug, some patients may experience short-term discomfort, which is mainly related to the decrease in drug concentration in the body and the recovery of tumor cell activity. Common symptoms include mild fatigue, loss of appetite, indigestion, or mild respiratory discomfort. Most of these symptoms are controllable and usually resolve gradually within a few days to a week or two. During the period of drug withdrawal, patients should closely observe their physical condition. If they experience obvious difficulty breathing, persistent high fever or severe pain, they should contact their doctor or go to the hospital in time.

In addition to physical reactions, there may be some risk of tumor "rebound" or disease progression after discontinuation of treatment. Clinically, it is recommended that patients should continue to undergo regular reexamination during the withdrawal period, including imaging examinations and blood index monitoring, in order to detect disease changes in a timely manner. If the disease relapses or progresses, doctors may consider restarting adagrasiib treatment or adjusting to other targeted drugs or chemotherapy regimens based on the patient's specific situation to ensure treatment continuity and efficacy.

In actual operation, life and diet management during drug withdrawal are also very important. Patients should ensure adequate rest, moderate exercise, a balanced diet, enhance immunity, and avoid taking drugs or health products that may affect drug metabolism at the same time. In addition, the patient's family or caregivers should pay attention to the patient's emotional changes and provide psychological support, because the discomfort after drug withdrawal and the uncertainty of the disease may cause anxiety or tension. In short, scientific drug withdrawal methods and standardized monitoring measures are important links in ensuring the safety and efficacy of adagrasiib treatment.

Reference link:https://www.drugs.com